Bienvenido al Med Info Alert. En la siguiente página podrás encontrar información de interés sobre anticoagulación, publicada en los meses de julio y agosto.
Si estás interesado en recibir alguna publicación de este mes, a continuación, puedes descargarla o acceder a tu cuenta para solicitarla.
Gjermeni D, et al. Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation. Eur Heart J Open. 2023
Fens T, et al. Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran. J Mark Access Health Policy. 2023
Kefale AT, et al. Clinical outcomes of oral anticoagulant discontinuation in atrial fibrillation: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2023
Cerezo Manchado JJ, et al. Impact of atrial fibrillation and anticoagulation on the risk of death, thromboembolic disease and bleeding in patients with COVID-19: the ACO-VID Registry. Curr Med Res Opin. 2023
Di J, et al. Comparison of clinical effects and costs among dabigatran etexilate, rivaroxaban and warfarin in elderly patients with atrial fibrillation. Am J Transl Res. 2023
Voss A, et al. Risk Profiles of New Users of Oral Anticoagulants Between 2011 and 2019 in Germany. Clin Epidemiol. 2023
Liu X, et al. Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry : Trends in antithrombotic therapy use in China. Thromb J. 2023
Wang YT, et al. Cardiac and renal outcomes of direct oral anticoagulants in patients with atrial fibrillation. Eur J Clin Invest. 2023
Guan C, et al. Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation Combined With Hypertension: A Multicenter, Retrospective Cohort Study. J Clin Pharmacol. 2023
Grosse M, et al. Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study. Int J Stroke. 2023
Ballestri S, et al. Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review. Adv Ther. 2023
Khan F, et al. Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism. BMJ Open. 2023
PC-ES-111565